Escape Bio, a biotech developing therapies for neurodegenerative disorders, has appointed Paul Wren to serve as its chief scientific officer. Wren was most recently senior director of neuroscience discovery at GlaxoSmithKline (NYSE: GSK). His experience also includes positions at Pfizer (NYSE: PFE) and Novartis (NYSE: NVS) subsidiary Sandoz.
The most advanced program from San Francisco-based Escape (formerly known as E-Scape Bio) is ESB1609. The experimental treatment is in Phase 1 testing for Niemann-Pick type C, a lysosomal storage disorder.